A Cross-Sectional Study on the Application of Chinese Patent Medicine in Immunosuppressive Therapy After Lung Transplantation

CHEN Yao; ZHANG Xianglin

doi:10.14009/j.issn.1672-2124.2020.10.026

您当前的位置：

首页 >

文章列表页 >

A Cross-Sectional Study on the Application of Chinese Patent Medicine in Immunosuppressive Therapy After Lung Transplantation

更新时间：2022-10-08

- A Cross-Sectional Study on the Application of Chinese Patent Medicine in Immunosuppressive Therapy After Lung Transplantation
- Vol. 20, Issue 10, Pages: 1255-1259(2020)
- 作者机构：
  
  1. 北京中医药大学中药学院
  2. 中日友好医院药学部
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2020.10.026
  CLC： R269
- Published：2020，
扫描看全文
[1]陈瑶,张相林.中成药在肺移植术后免疫抑制治疗中应用的横断面研究[J].中国医院用药评价与分析,2020,20(10):1255-1259.

CHEN Yao, ZHANG Xianglin. A Cross-Sectional Study on the Application of Chinese Patent Medicine in Immunosuppressive Therapy After Lung Transplantation. [J]. 20(10):1255-1259(2020)
[1]陈瑶,张相林.中成药在肺移植术后免疫抑制治疗中应用的横断面研究[J].中国医院用药评价与分析,2020,20(10):1255-1259. DOI： 10.14009/j.issn.1672-2124.2020.10.026.

CHEN Yao, ZHANG Xianglin. A Cross-Sectional Study on the Application of Chinese Patent Medicine in Immunosuppressive Therapy After Lung Transplantation. [J]. 20(10):1255-1259(2020) DOI： 10.14009/j.issn.1672-2124.2020.10.026.

摘要

目的:对单中心肺移植患者术后免疫抑制维持治疗中中成药的应用情况进行横断面研究

探讨中成药临床使用特点

为临床合理使用中成药提供参考。方法:收集2017年3月至2019年8月于中日友好医院就诊的肺移植患者的术后用药信息

利用SAS 9. 4软件对相关数据进行分析。结果:166例肺移植患者中

术后使用中成药的共104例

占62. 65%。肺移植患者术后免疫抑制维持治疗所用中成药涉及25个品种

类别包括解表剂、泻下剂、理气剂、清热剂、祛瘀剂、化痰止咳平喘剂、扶正剂和安神剂

使用病例数排序居前3位的中成药为百令胶囊、金花清感颗粒和尿毒清颗粒。104例术后使用中成药的患者中

34例（占32. 69%）患者联合应用2种及2种以上的中成药。中成药不合理应用主要表现为无中医诊断、重复用药和超剂量用药。肺移植术后免疫维持治疗中

使用中成药患者与未使用中成药患者的他克莫司血药浓度比较

差异有统计学意义（P <0. 000 1）。结论:肺移植患者术后免疫抑制维持治疗中使用中成药应考虑方案的合理性

遵循辨证辨病相结合的原则

注重药学监护

以确保临床用药的合理性。

Abstract

OBJECTIVE: To conduct a cross-sectional study on the application of Chinese patent medicine in immunosuppressive maintenance therapy on patients underwent single-center lung transplantation

to probe into the characteristics of clinical application of Chinese patent medicine

so as to provide references for rational application of Chinese patent medicine. METHODS: Postoperative medication information of patients undergoing lung transplant admitted into the China-Japan Friendship Hospital from Mar. 2017 to Aug. 2019

SAS 9. 4 was adopted to analyze related data. RESULTS: Among the 166 patients underwent lung transplantation

104 patients had used Chinese patent medicine

accounted for 62. 65%. 25 categories of Chinese patent medicine were involved in postoperative immunosuppressive maintenance therapy in patients underwent lung transplantation

including diaphoretic prescription

purgative prescription

qi-regulating prescription

heat-clearing prescription

stasis-removing prescription

phlegmresolving and cough and asthma relieving prescription

body-strengthen prescriptions and tranquillizer prescriptions

the top 3 Chinese patent medicine ranked by case load were respectively Bailing capsule

Jinhua Qinggan granule and Niaoduqing granule. Of the 104 patients used Chinese patent medicine after surgery

34 patients（ 32. 69%） had been applied 2 or above drug combination. The irrational application of Chinese patent medicine mainly including no TCM diagnosis

repeated dose and over-dose. In the immunosuppressive maintenance therapy after lung transplantation

the difference in blood concentration of tacrolimus between patients using and not using Chinese patent medicine was statistically significant（ P < 0. 000 1）. CONCLUSIONS: The rationality of therapeutic regimen of Chinese patent medicine should be considered in the immunosuppressive maintenance therapy after lung transplantation

the principle of syndrome differentiation with disease differentiation should be followed

and pharmaceutical care should be paid attention to ensure the rationality of clinical medication.

关键词

肺移植中成药横断面研究

Keywords

Lung transplantationChinese patent medicineCross-sectional study

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Analysis of Clinical Status of Guiding Herbs for Chinese Patent Medicine Included in Chinese Pharmacopoeia （Part Ⅰ）

Review on 6 000 Prescriptions of Chinese Patent Medicine for Digestive System Disease and Analysis on Its Medication Rationality

Systematic Review of Efficacy and Safety of Oral Chinese Patent Medicine in the Treatment of Adult Cough Variant Asthma

Statistical Analysis on Application of Chinese Patent Medicine by Western Clinicians in A General Hospital Based on Information System and Questionnaire Survey

Investigation and Analysis on Cognition for Rational Application of Chinese Patent Medicine Among Different Categories of Medical Personnel

Related Author

杨丽萍

张碧华

邵晖

叶爱军

ZENG Weixin

ZHANG Mo

LIU Min

GU Hongyan

Related Institution

Audit Section, Beijing Xuanwu Traditional Chinese Medicine Hospital

Beijing Hospital

Beijing Key Laboratory of Evaluation on Clinical Rational Drug Application

Dept. of Pharmacy, Beijing Shijitan Hospital Affiliated to Capital Medical University

Dept.of Respiratory and Critical Care Medicine,the First Affiliated Hospital of Guangxi University of Chinese Medicine

⁰